Intensive Chemotherapy and Early Rituximab Use for Aggressive Mature B-cell Non-Hodgkin Lymphoma in Children and Adolescents up to 18 Years
Led by Children's Cancer Group, China · Updated on 2026-06-04
87
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether combining intensive chemotherapy with early and frequent use of Rituximab can improve event-free survival EFS and overall survival OS in children and adolescents with aggressive mature B-cell Non-Hodgkin Lymphoma B-NHL. This study builds on previous research showing varying survival rates based on disease stage and treatment, aiming to enhance outcomes especially for high-risk patients.
The study involves different treatment groups based on disease stage and risk factors. For early-stage disease, patients may receive 3 to 5 chemotherapy courses with intrathecal injections. Higher-risk groups receive more intensive chemotherapy cycles combined with multiple Rituximab doses, including six injections for the highest risk group, along with additional chemotherapy cycles for very high-risk patients. Treatments include various chemotherapy drugs such as Cyclophosphamide, Vincristine, Cytarabine, Doxorubicin, Prednisone, Ifosphamide, Etoposide, Methotrexate, and Vindelsine, administered according to detailed schedules.
Participants will be closely monitored through scheduled follow-up visits to assess their response and any side effects. Researchers will measure event-free survival over three years as the primary outcome, with overall survival over the same period as a secondary outcome. The study will track treatment adherence, toxicity management, and use intrathecal injections for central nervous system involvement. Total participation duration extends up to or beyond three years, including ongoing evaluations to determine the effectiveness and safety of the treatment approach.
CONDITIONS
Brief Title
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
Research Team
Y
Yi-jin Gao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically or cytologically confirmed mature B-cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (including Burkitt, DLBCL, PMLBL, or aggressive mature B-cell NHL not otherwise specified)
Ability to comply with scheduled follow-up and toxicity management
Signed informed consent
You will not qualify if you...
Follicular lymphoma, MALT, and nodular marginal zone lymphoma are excluded
History of congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, or previous malignancy of any type
Known positive HIV serology
Evidence of pregnancy or lactation
Past or current anti-cancer treatment except corticosteroids for less than one week
Tumor cells negative for CD20
Prior exposure to Rituximab
Hepatitis B carrier status or positive hepatitis B serology
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Several months depending on risk group and treatment cycles
Participants receive intensive chemotherapy combined with early, adequate, and intensive use of Rituximab according to their risk group. Treatment includes multiple cycles of chemotherapy drugs and Rituximab injections tailored to disease stage and risk.
Multiple visits for chemotherapy and Rituximab administration over treatment cycles
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Evaluating Glofitamab Alone and With Chemoimmunotherapy for Children and Young Adults With RelapsedRefractory Mature B-Cell Non-Hodgkin Lymphoma
Intensive Chemotherapy and Early Rituximab Use for Aggressive Mature B-cell Non-Hodgkin Lymphoma in Children and Adolescents up to 18 Years
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups.
A prospective multicenter study investigating rituximab combined with intensive chemotherapy in newly diagnosed pediatric patients with aggressive mature B cell non-Hodgkin lymphoma (CCCG-BNHL-2015): a report from the Chinese Children's Cancer Group.